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Available online 12 December 2015The anaplastic lymphoma kinase (ALK) fusion oncogene is observed in 3%–5% of non-small cell lung cancer
(NSCLC). Crizotinib and ceritinib, a next-generation ALK tyrosine kinase inhibitor (TKI) active against
crizotinib-refractory patients, are clinically available for the treatment of ALK-rearranged NSCLC patients, and
multiple next-generation ALK-TKIs are currently under clinical evaluation. These ALK-TKIs exhibit robust clinical
activity in ALK-rearranged NSCLC patients; however, the emergence of ALK-TKI resistance restricts the therapeu-
tic effect. To date, various secondary mutations or bypass pathway activation-mediated resistance have been
identiﬁed, but large parts of the resistance mechanism are yet to be identiﬁed. Here, we report the discovery of
p-glycoprotein (P-gp/ABCB1) overexpression as a ceritinib resistance mechanism in ALK-rearranged NSCLC pa-
tients. P-gp exported ceritinib and its overexpression conferred ceritinib and crizotinib resistance, but not to
PF-06463922 or alectinib, which are next-generationALK inhibitors. KnockdownofABCB1or P-gp inhibitors sen-
sitizes the patient-derived cancer cells to ceritinib, in vitro and in vivo. P-gp overexpression was identiﬁed in
three out of 11 cases with in ALK-rearranged crizotinib or ceritinib resistant NSCLC patients. Our study suggests
that alectinib, PF-06463922, or P-gp inhibitor with ceritinib could overcome the ceritinib or crizotinib resistance
mediated by P-gp overexpression.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The anaplastic lymphoma kinase (ALK) fusion oncogene caused by
chromosomal rearrangement has been observed in a variety of human
malignancies, including ALK-rearranged non-small cell lung cancer
(NSCLC), which was identiﬁed in 2007 (Soda et al., 2007). ALK gene re-
arrangement results in the constitutive expression and activation of an
ALK fusion protein, which has been shown to strongly drive oncogene-
sis. To target ALK-rearranged NSCLC, the oral ALK and v-ros avian ur2
sarcoma virus oncogene homolog 1 (ROS1) inhibitor crizotinib have
been used. Two randomized phase 3 studies of crizotinib showed signif-
icantly longer progression-free survival (PFS; 7.7 months vs 3.0 months
in the second-line study and 10.9months vs 7.0 months in the ﬁrst-line
study) and higher overall response rate [ORR; 65% (113/173) vs 20%
(34/174) in the second-line study and 74% (128/172) vs 45% (77/171)
in the ﬁrst-line study] compared with those of chemotherapy (Shawthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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shown signiﬁcant treatment efﬁcacy in ALK fusion-positive NSCLC
patients, tumor relapse because of acquired resistance has been ob-
served. Crizotinib resistance was shown to be caused by various types
of secondary mutations in the ALK kinase domain, by ALK fusion gene
ampliﬁcation, or by activation of the epidermal growth factor receptor
(EGFR) or KIT (v-kit hardy-zuckerman 4 feline sarcoma viral oncogene
homolog)-mediated bypass pathways (Doebele et al., 2012; Katayama
et al., 2012; Sasaki et al., 2011). Crizotinib has also been shown to be rel-
atively ineffective for cancer that has metastasized to the brain because
of poor blood–brain barrier (BBB) penetration by P-glycoprotein (P-gp)
overexpression (Costa et al., 2011; Chuan Tang et al., 2014).
To overcome crizotinib resistance, various next-generation ALK
inhibitors have been evaluated in clinical trials. Among these, two
ALK-tyrosine kinase inhibitors (TKIs) alectinib and ceritinib, have re-
vealed prominent responses in both ALK-TKI-naïve and crizotinib-
treated patients (Sakamoto et al., 2011; Shaw et al., 2014; Gadgeel
et al., 2014; Seto et al., 2013; Marsilje et al., 2013). Encouraged by
these signiﬁcant clinical responses (Shaw et al., 2014), ceritinib was ap-
proved for clinical use by theUS Food andDrug Administration (FDA) in
2014 and EuropeanMedicines Agency (EMA) in 2015, and alectinibwas
approved by the Pharmaceuticals and Medical Devices Agency of Japan
in 2014 and FDA in 2015 (Seto et al., 2013). However, it is expected that
next-generation ALK inhibitor-resistant tumors will also eventually de-
velop via multiple mechanisms. To date, a few ceritinib-resistant muta-
tions in the ALK kinase domain have been identiﬁed in patients who
experienced a relapse during ceritinib therapy (Friboulet et al., 2014).
In human cancer, ABCB1/P-gp, ABCC1/multidrug resistance-
associated protein 1 (MRP1), and ABCG2/breast cancer resistance
protein (BCRP) are well-known causes of multidrug resistance tomulti-
ple chemotherapeutic agents, such as taxane and vinca alkaloids
(Gottesman et al., 2002). Therefore, much effort has been devoted for
developing the ATP-binding cassette (ABC)-transporter inhibitors.
Among the ABC-transporter inhibitors, dofequidar fumarate (MS209)
was identiﬁed as an orally active, quinoline-derived inhibitor of
ABCB1/P-gp. In preclinical studies, MS209 reversed multidrug resis-
tance in ABCB1 — and ABCC1-expressing cancer cells in vitro. In addi-
tion, oral administration of MS209 enhanced the antitumor activity of
adriamycin, vincristine, and docetaxel in vivo (Naito et al., 2002;
Nakanishi et al., 1997; Sato et al., 1995). Thus, MS209 has been a
promisingmultidrug resistance-reversing agent and has been evaluated
in clinical trials. The results of phase III clinical evaluations of MS209 for
breast cancer treatment showed a relative improvement and increased
response rate in patients who received MS209 plus cyclophosphamide,
doxorubicin, and ﬂuorouracil (CAF); however, differences did not
reach statistical signiﬁcance. However, the subgroup analysis sug-
gested that MS209 plus CAF therapy displayed signiﬁcantly im-
proved PFS and overall survival (OS) in therapy-naive patients
(Saeki et al., 2007). To date, a large number of ABC-transporter inhibi-
tors have been developed, but failed because of undesirable toxicities
(Fletcher et al., 2010).
Here, we report on our experience with a metastatic lung adenocar-
cinoma patient positive for ALK rearrangement who initially responded
to ceritinib treatment. Meanwhile, the disease ultimately relapsed and
failed to respond to subsequent chemotherapy or crizotinib therapy.
We identiﬁed a ceritinib resistance mechanism caused by P-gp overex-
pression in the tumor. In vitro studies using ceritinib-resistant patient-
derived cells have revealed that ceritinib is a P-gp substrate, and P-gp
overexpression confers ceritinib and crizotinib resistance but does not
confer alectinib or PF-06463922 resistance. In cell-line and murine-
xenograft experiments, patient-derived P-gp-overexpressing cells
responded to ceritinib plus P-gp inhibitor combination treatment, or
alectinib or PF-06463922 which is not a P-gp substrate. In addition,
we identiﬁed P-gp overexpression in two out of 10 crizotinib- or
ceritinib-resistant metastatic ALK rearranged NSCLC patients and in
one out of 31 ALK-TKI naïve tumors. The ALK-TKI naïve patient withP-gp overexpression had large-cell neuroendocrine carcinoma. These
results suggest that P-gp overexpression potentially affects the response
to ALK-TKIs, signifying the importance of obtaining biopsy samples fol-
lowing precise characterization of both pre- and post- ALK-TKI-treated
tumors in ALK-rearranged NSCLC patients to achieve maximum
therapeutic effects.
2. Material and Methods
2.1. Patients
Biopsies of ALK-TKI-resistant tumors from 10 ALK-positive NSCLC
patients with acquired resistance were obtained between January
2010 and December 2013. Standard histopathological analysis was per-
formed to conﬁrm the diagnosis of malignancy and the histological sub-
type. For all samples, total nucleic acid was isolated as described below.
In cases with sufﬁcient tissue samples, we also performed ﬂuorescence
in situ hybridization (FISH) and immunohistochemical (IHC) analyses
as described below. Electronic medical records were retrospectively
reviewed to obtain clinical information in accordance with an institu-
tional review board (IRB)-approved protocol.
The patient submitted written informed consent for genetic and cell
biological analyses, whichwere performed in accordancewith protocols
approved by the IRBs of the Japanese Foundation for Cancer Research or
Massachusetts General Hospital Cancer Center (Boston, MA, USA).
2.2. Establishment of Patient-derived Cancer Cell Lines
Tumors from patients with ALK-positive NSCLC patients were
biopsied. Standard histopathological analysis was performed to conﬁrm
a diagnosis of malignancy and the histological subtype. We also per-
formed FISH and IHC analyses as described below. Cell lines were
established from malignant ﬂuid or biopsy specimens after a sufﬁcient
amount of tissue was obtained. JFCR018-1 cell line was established
from malignant ﬂuid from an ALK-TKI-naïve ALK-rearranged NSCLC
patient. JFCR018-1 cells harbor EML4-ALK v1 without secondary
mutation.
2.3. JFCR013 Patient Treatment History
In May 2012, a 47-year-old woman with no history of smoking was
diagnosed withmetastatic lung adenocarcinomawith an ALK transloca-
tion at a tumor-node-metastasis (TNM) clinical stage of T4N3M1a.
After two cycles of chemotherapy (cisplatin and pemetrexed), disease
progression was conﬁrmed by computed tomography (CT) scan
(Fig. S1C). The patient was subsequently enrolled in a phase-I clinical
trial of ceritinib (LDK378) treatment, and 6 weeks after initiation of
ceritinib treatment, a remarkable response was observed (PR, 38.9%
tumor shrinkage, Fig. S1A). However, 6 months later, the disease had
progressed on ceritinib therapy. To identify themechanisms of ceritinib
resistance, we obtained a biopsy specimen and pleural ﬂuidwithmalig-
nant cells from ceritinib-resistant tumors in the patient, with which we
established the cell lines JFCR013-1 and JFCR013-2. The existence of ALK
rearrangement was conﬁrmed by FISH analysis. After ceritinib therapy,
the patient received one cycle of docetaxel, to which she failed to re-
spond, and we established the cancer cell line JFCR013-3 from malig-
nant ﬂuid in the right pleural cavity. The patient was then treated
with crizotinib for 6 weeks. Because there was no measureable region,
and the thoracentesis was performed during crizotinib treatment, the
response to crizotinib was not evaluable (NE). During crizotinib treat-
ment, we obtained two additional specimens of malignant ﬂuid from
the right pleural cavity and established the cell lines JFCR013-4 and
JFCR013-5. The patient died, and an autopsy was performed. From all
disease sites that were examined, tumor samples were stored and cell
lines were established from primary and metastatic tumors, which in-
cluded normal lung tissue (JFCR013-6-4) (Table S1 and Fig. S1D).
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FISH analysis of EGFR, cMET, and cKIT and the break-apart ALK FISH
assay were used to identify gene copy numbers and ALK gene rear-
rangements in malignant tissue specimens. Complementary DNA from
malignant tissues and cells was used to amplify EML4-ALK and ABCB1
(P-gp). RT-PCR products were sequenced using the Sanger method.
Genomic DNA extracted from primary cancer cells from a malignant
ﬂuid sample was used for deep sequencing of a panel of 48 cancer-
related genes (MiSeq Cancer Panel; Illumina, Inc., San Diego, CA, USA).
Cell culturing, sequencing, IHC, and FISH procedures and characteriza-
tion of P-gp are described in detail in the following methods.
2.5. Deep Sequencing
The samples were processed on the MiSeq platform with a TruSeq
Amplicon Cancer Panel (Illumina, Inc.), which is designed to detect
well-known somaticmutations of 48 genes (Table S2). Somatic variants
were called using the Somatic Variant Caller (Illumina, Inc.) and
annotated using the ANNOVAR (Wang et al., 2010) software tool
(http://www.openbioinformatics.org/annovar/) and in-house scripts.
2.6. Reagents
Alectinib, ceritinib (LDK378) and PF-06463922 were purchased
from Active Biochem (Hong Kong, China). TAE684 was purchased
from Chemietek (Indianapolis, IN, USA), crizotinib from Shanghai
Biochempartner (Shanghai, China), and verapamil and MS209 from
Sigma-Aldrich (St. Louis, MO, USA). 14C-labeled ceritinib (Fig. S7A)
was kindly provided byNovartis PharmaAG (Basel, Switzerland). 3H-la-
beled paclitaxel was purchased from American Radiolabeled Chemicals
Inc. Each compound was dissolved in dimethyl sulfoxide for in vitro
experiments.
2.7. Isolation of Genomic DNA, Total RNA Preparation, and Sequencing of
the ALK Fusion Gene
Genomic DNA was isolated from cell pellets or fresh frozen speci-
mens using the DNeasy Blood & Tissue kit (Qiagen, Hilden, Germany)
according to the manufacturer's protocol. Total RNA was isolated from
cell pellets or fresh frozen specimens using theRNeasymini kit (Qiagen)
according to the manufacturer's instructions. Each exon of the ALK
kinase domain (exon 21–27), EML4-ALK, or ALK kinase domain was
PCR-ampliﬁed from genomic DNA or cDNA synthesized from total
RNA with oligo-dTs using the KOD Plus v2 kit (Toyobo Co., Ltd., Osaka,
Japan) and bidirectionally sequenced by the Sanger method.
2.8. FISH Analysis
FISH analyses for ALK, MET, KIT, and EGFR were performed using
formalin-ﬁxed parafﬁn-embedded tissues with in-house probes made
from BAC clones (the exact clone names are available upon request).
Images were captured with an Olympus BX51 ﬂuorescent microscope
equipped with a charge-coupled device camera (DP71; Olympus,
Tokyo, Japan).
2.9. Cell Culture Conditions
H3122, K562, and K562-derived vincristine-resistant (K562/VCR)
cells were cultured in Roswell ParkMemorial Institute (RPMI) 1640me-
dium supplemented with 10% fetal bovine serum (FBS; R-10). The
H3122 cell line was obtained from the MGH/CMT Lab. JFCR013 cell
lines derived from a ceritinib-resistant patient and the JFCR018-1 cell
line established from ALK-TKI-naïve patient were cultured in RPMI
1640/F-12 medium supplemented with 15% FBS and 20 mM Hepes
buffer (pH 7.5).2.10. Survival Assays
For 72-h drug treatments, 2000–3000 cells were plated in replicates
of 3–6 into 96-well plates. Followingdrug treatment, cellswere incubat-
ed with CellTiter-Glo assay reagent (Promega Corp., Madison, WI, USA)
for 10 min and luminescence was measured using a Centro LB 960
microplate luminometer (Berthold Technologies GmbH & Co. KG,
Bad Wildbad, Germany). The data were graphically displayed using
GraphPad Prism graphing software (v5.0; GraphPad Software, Inc., San
Diego, USA). Half-maximal inhibitory concentration (IC50) values
were determined using a non-linear regression model with a sigmoidal
dose–response curve (GraphPad).
2.11. Immunoblot Analysis
Lysates were prepared as previously described (Engelman et al.,
2007b; Katayama et al., 2012). In brief, equal amounts of lysates
were electrophoresed and immunoblotted with antibodies against
phospho-ALK (Tyr1604), ALK (C26G7), phospho-STAT3 (Thr705),
STAT3, phospho-p42/44 ERK/MAPK (Thr202/Tyr204), p42/44 ERK/
MAPK, phospho-Akt (Ser473) (D9E), panAkt (C67E7), phospho-S6 ribo-
somal protein (Ser240/244, D68F8), S6 ribosomal protein (54D2), P-gp
(Cell Signaling Technology, Inc., Beverly, MA, USA), GAPDH (6C5; EMD
Millipore, Billerica, MA, USA), and β-actin (Sigma-Aldrich).
2.12. IHC Analysis
Formalin-ﬁxed, parafﬁn-embedded tissue specimens were sliced by
a thickness of 4 μm, and the sections were placed on silane-coated
slides. For antigen retrieval, slides were heated for 45 min at 105 °C in
an antigen retrieval solution at pH 9.0 (Nichirei Biosciences, Inc.,
Tokyo, Japan). Antigen–antibody complexes were visualized with
Histoﬁne Simple Stain MAX PO detection reagent (Nichirei Biosciences,
Inc.). The ALK Detection Kit (Nichirei Biosciences, Inc.), which is
based on the intercalated antibody-enhanced polymer (iAEP) method
(Takeuchi et al., 2009), was used for anti-ALK IHC analysis. The staining
procedure was performed using the Histostainer automated staining
system (Nichirei Biosciences, Inc.). For IHC of P-gp, anti-ABCB1 (P-gp)
monoclonal antibody (6C4.2, Chemicon International Inc.) was used.
Positivity for P-gp was standardized using KB3-1 (negative control)
and ABCB1 overexpressed KB3-1 (KB3-1/ABCB1, positive control).
2.13. Retroviral Infection
Retroviral expression vectors encoding shRNA against P-gp or
control shRNA were purchased from Sigma-Aldrich and viruses were
produced as previously described (Engelman et al., 2007a). After retro-
viral infection, cells were kept in puromycin (1.0 μg/mL) for 2 weeks.
2.14. Cellular Uptake of 14C-ceritinib and 3H-paclitaxel
Cellular uptake of 14C-ceritinib and 3H-paclitaxel was measured in a
culture medium. Tumor cells (1 × 106) were incubated at 37 °C in the
presence of [14C]ceritinib (100 nM; speciﬁc activity, 7.4 MBq/mg) and
verapamil or MS209. After incubation, the cells were washed with PBS
and lysed with lysis buffer containing 1% Triton X-100. The cell lysates
and liquid scintillation cocktail (ACS II) were mixed well, and the
cellular uptake of ceritinib was measured using a liquid scintillation
counter (Beckman Coulter, Inc., Pasadena, CA, USA).
2.15. Mouse Experiment
JFCR013-2 cells (1 × 106) were subcutaneously injected into
5–6-week-old female BALB/c-nu/nu (nude) mice (Charles River
Laboratories, Yokohama, Japan). The mice were checked twice weekly
for palpable tumor formation and then euthanized. The tumors were
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injected into another 5–6-week-old female BALB/c nude mouse.
Tumor size was measured every other day using a caliper and tumor
volumes were deﬁned as (longest diameter) × (shortest diameter)2/2.
When the tumor size reached approximately 100 mm3, the mice were
sorted into ﬁve equal groups. Then, the nudemice were orally adminis-
tered ceritinib (50 mg/kg) with or without MS209 (200 mg/kg) or
alectinib (CH5424802). MS209 was administered 30 min prior to
ceritinib treatment. Body weight and tumor size were measured everyFig. 1. Response to ceritinib and obtained tumor samples from ALK-rearrangedNSLCL patient. (A
ment (left), after response to ceritinib treatment (center), and at the time of disease progressi
pleural effusion at the time of disease progression on ceritinib. The picturewas taken 4 days befo
of JFCR013 and time line of the treatment, examination, and sample acquisition. (D) A summar
the EML4-ALK and ALK kinase domain and deep sequencing of the ALK kinase domain (Illumina
ALK probe (green) of a formalin-ﬁxed parafﬁn-embedded specimen from the patient. ALK rearr
Nuclei were stained with 4′,6-diamidino-2-phenylindole.3 days. All animal procedures were performed in accordance with
protocols approved by the Japanese Foundation for Cancer Research
Animal Care and Use Committee.2.16. Statistical Analysis
All data are presented as means ± standard deviation. Statistical
analysis was performed using the two-tailed Student's t-test or) An axial CT scan of the chest showing the patient's tumor burden prior to ceritinib treat-
on while on ceritinib (right). (B) X-ray and CT scan of the chest showing accumulation of
re thoracentesis fromwhich the JFCR013-2 cell linewas established. (C) Treatment history
y of all obtained specimens and genetic alteration of ALK analysis by Sanger sequencing of
TruSeq amplicon panel). (E) Break-apart FISH analysiswith a 5′-ALK probe (red) and a 3′-
angement was indicated by the presence of individually isolated red 3′-ALK green probes.
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(P)-values are indicated as ***P b 0.001, **P b 0.01 and *P b 0.05.
3. Results
3.1. Identiﬁcation of Ceritinib Resistance Without a Secondary Resistance
Mutation in ALK
A metastatic ALK-rearranged lung adenocarcinoma patient was en-
rolled in a phase-I clinical trial of ceritinib (LDK378) treatment. Evalua-
tion performed 6weeks after initiation of ceritinib treatment revealed a
marked treatment response (PR, 38.9% tumor shrinkage). However, 6
months later, it was observed that the disease had progressed while
the patient was still receiving ceritinib therapy (Fig. 1A). To identify
the mechanisms of ceritinib resistance, we obtained a biopsy specimen
and malignant pleural ﬂuid from ceritinib-resistant tumors in the pa-
tient by which we established the cell lines JFCR013-1 and JFCR013-2Fig. 2. Ceritinib-refractory patient-derived cells were resistant to ceritinib and crizotinib
concentrations of crizotinib, ceritinib, alectinib, or TAE684 for 72 h. After incubation, cell viab
table (C). (D–G) JFCR-013-2 and H3122 cells were treated with the indicated concentration of
by immunoblotting with the indicated antibodies.(Fig. 1B–D, Table S1). The ALK rearrangement was conﬁrmed by FISH
analysis (Fig. 1E), and the fusion of exon 13 of EML4 to exon 20 of ALK
was identiﬁed by RT-PCR from JFCR013-2 cells (Fig. 1D). Upon relapse,
the patient received one cycle of docetaxel, but the tumor failed to
respond, and we established the JFCR013-3 cancer cell line from
malignant pleural ﬂuid in the right lung (Fig. 1C). The patient was
subsequently treatedwith crizotinib, duringwhichwe obtained two ad-
ditional samples of malignant ﬂuid from the right pleural cavity and
established the cell lines JFCR013-4 and JFCR013-5 (Fig. 1C, D, and
Table S1). The patient died, and an autopsywas performed. From all dis-
ease sites thatwere examined, tumor sampleswere stored and cell lines
established from primary and metastatic tumors, which included the
normal lung tissue (Fig. 1D, S1, and Table S1). None of the tumor sites
carried amutation in the kinase domain of the EML4-ALK fusion protein
(Fig. 1D). To further identify potential resistance mechanisms, we per-
formed amplicon sequencing analysis of a panel of 48 genes typically
implicated in cancer (Table S2). The analysis conﬁrmed the absence ofbut not to alectinib. (A–C) JFCR013-2 or H3122 cells were treated with the indicated
ility was measured using the CellTiter-Glo assay. Calculated IC50 values are shown in the
ceritinib (D), crizotinib (E), alectinib (F), or TAE684 (G) for 3 h. Cell lysates were analyzed
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cMET, and cKIT revealed no ampliﬁcation in JFCR013-2 and JFCR013-5
specimens (data not shown).
3.2. P-gp Overexpression-mediated Ceritinib and Crizotinib Resistance
Next, we examined the sensitivity of various selective ALK inhibitors
to JFCR013-2 cells derived from ceritinib-resistant tumor samples.
JFCR013-2 cells showed marked crizotinib and ceritinib resistance, but
were sensitive to alectinib and TAE684 (Fig. 2A–C). Furthermore,Fig. 3. P-gp was highly expressed in JFCR-013 cells. (A) P-gp expression in the indicated cell li
analyzed by immunoblotting. (C) Cell surface P-gp expression analyzed by ﬂow cytometry aft
(D) ABCB1 or BCRP (ABCG2) mRNA expression levels analyzed by quantitative RT-PCR. Relativ
ND (not detected) means no PCR amplicon of ABCB1 or ABCG2 was detected.ceritinib as well as crizotinib effectively inhibited ALK phosphorylation
and downstream phospho-AKT and phospho-ERK activation in H3122
cells, which are EML4-ALK harboring ALK-TKI sensitive cells. On the
other hand, JFCR013-2 cells required higher concentration of crizotinib
or ceritinib to suppress phospho-ALK than H3122 cells (Fig. 2D and E).
In contrast, TAE684 and alectinib inhibited phospho-ALK in both
H3122 and JFCR013-2 cells to a similar extent (Fig. 2F and G). Because
the disease did not respond to docetaxel treatment after relapsed on
ceritinib, we treated JFCR013-2 cells with docetaxel. As the result, com-
paredwithH3122 or K562 cells, JFCR013-2 cells were highly resistant tones was analyzed by immunohistochemistry. (B) P-gp, ALK or β-actin protein expression
er incubation of each cell line with P-gp monoclonal antibody (blue) or control IgG (red).
e mRNA expression was calculated using β-actin (ACTB) mRNA expression as reference.
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viously been established from a vincristine-resistant K562 cell line by
treating increasing concentration of vincristine, and that had been
shown to be resistant to docetaxel by overexpressing P-gp via ABCB1
gene ampliﬁcation (Fig. S2B, S2C) (Sugimoto et al., 1987; Naito et al.,
2002). On the other hand, each of these cell lines showed similar sensi-
tivity to cisplatin which is not a substrate of P-gp (Fig. S2D). ABC trans-
porters such as P-gp (ABCB1) or BCRP (ABCG2), play an important role
in chemotherapeutic drug resistance (Gottesman et al., 2002). In addi-
tion, it is also known that ABC transporters are highly expressed in the
cancer stem/initiating cells (CSCs), and confer CSC resistance tomultiple
chemotherapeutic drugs (Katayama et al., 2009). Therefore, we hypoth-
esized that ceritinib and crizotinib were actively exported from the
JFCR013-2 cells by ABC transporter(s), resulting in ceritinib and crizo-
tinib resistance. Thus, we examined expression levels of the ABC trans-
porter P-gp (ABCB1). As we expected, P-gp expressionwas signiﬁcantly
upregulated in the established ceritinib-resistant cell lines JFCR013-2
and JFCR013-5 at a level similar to that in ABCB1-transfected KB3-1
cells, but it was not upregulated in parental KB-3-1 cells or JFCR018-1
cells established from another ALK-TKI treatment-naïve ALK-
rearranged NSCLC patient (Fig. 3A and B). Using the anti-P-gpmono-
clonal antibody MRK-16, which recognizes the extracellular domainFig. 4. P-gp overexpression was observed only in the tumor after ceritinib treatment. (A) IHC an
and JFCR013-6-1 (autopsy) specimens. (B) P-gp protein expression in the indicated cell lines an
autopsy specimens was analyzed by quantitative RT-PCR. In particular, JFCR013-6-4 reﬂects n
expression as a reference.of P-gp (FitzGerald et al., 1987), we conﬁrmed surface P-gp expression
in JFCR013-2 cells (Fig. 3C). Furthermore, themRNA levels of ABCB1, but
not those of ABCG2, were upregulated in the ceritinib-resistant cells
lines and tumors (Fig. 3D). Next, we examined P-gp expression in the
stored clinical specimens. P-gp overexpression and upregulation of
ABCB1 mRNA were also observed in the ceritinib-resistant tumor
(JFCR013-2 and JFCR013-6-1) but not in the pre-ceritinib-treated
tumor biopsy specimen (JFCR013-pre; Fig. 1A, C and Table S1), and
ALK expression was maintained throughout the treatment period
(Fig. 4A). In contrast to the K562/VCR cells, JFCR013-2 cells showed no
marked ampliﬁcation of ABCB1 (Fig. S2C), and no ABCB1 mutation in
the JFCR013-2 cell line was observed.
3.3. P-gp-knockdown or Overexpression Affects the Sensitivity to Ceritinib
and Crizotinib
To examine whether P-gp overexpression contributes to ceritinib
resistance, we established ABCB1-knockdown cells using shRNA. sh-
ABCB1 (#86 and #87), but not control shRNA, decreased P-gp expres-
sion and sensitized the cells to ceritinib and crizotinib (Fig. 5A and B).
Conversely, we established H3122 cells overexpressed P-gp (Fig. 5C).
As shown in Fig. 5D, E, S3 and S4, P-gp overexpressing H3122 cellsalysis of P-gp or ALK protein expression in JFCR-013-pre and ceritinib-resistant JFCR013-2
d in autopsy specimens analyzed by immunoblotting. (C) ABCB1mRNA expression level in
ormal lung tissue. Relative mRNA expression was calculated using β-actin (ACTB) mRNA
Fig. 5. P-gp overexpression confers ceritinib and crizotinib resistance. (A) P-gp protein expression in the indicated shRNA-induced cells analyzed by immunoblotting. (B) JFCR013-2- and
shABCB1-induced JFCR013-2 cells treated with serially diluted concentrations of ceritinib or crizotinib for 72 h. After incubation, cell viability was measured by CellTiter-Glo Assay.
Calculated IC50 values are shown in the table. (C) P-gp and β-actin protein expression in H3122 and ABCB1-overexpressing H3122 cells analyzed by immunoblotting. (D, E) H3122 or
ABCB1-overexpressing H3122 cells treated with the indicated concentrations of ceritinib (left) or crizotinib (right) for 72 h. After incubation, cell viability was measured using the
CellTiter-Glo assay. Calculated IC50 values are shown in (E).
61R. Katayama et al. / EBioMedicine 3 (2016) 54–66showed signiﬁcant ceritinib and crizotinib resistance, but did not show
alectinib or PF-06463922 resistance, a potent next-generation ALK
inhibitor under clinical evaluation, which is also showed active
against multiple crizotinib resistant mutants (Johnson et al., 2014).
Indeed, the patient-derived JFCR013-2 cells were highly sensitive to
PF-06463922 (Fig. S5).
3.4. P-gp-mediated Ceritinib Pump-out Confers Resistance
Next,we examined if ceritinibwas in fact exported by the ABC trans-
porter P-gp. Ceritinib uptake wasmeasured by incubating the cells with
14C-labeled ceritinib (Fig. S6A). In ceritinib-resistant JFCR013-2 cells, the
incorporation of 14C-ceritinib became constant after 8 h, whereas treat-
ment with the P-gp inhibitor MS209 (Sato et al., 1995) or verapamil
(Tsuruo et al., 1981) constantly increased cellular uptake of 14C-ceritinib.
In contrast, sh-ABCB1 inhibited ceritinib pump-out, resulting in a contin-
uous intercellular accumulation of 14C-ceritinib (Fig. 6A). Similar results
were observed in vincristine-resistant P-gp-overexpressing K562/VCRcells, but not in K562 parental cells (Fig. 6B). In addition, when
JFCR013-2 cells were incubated with 3H-paclitaxel, which is a sub-
strate of P-gp, the incorporation of 3H-paclitaxel was restored by
MS209 or verapamil treatment (Fig. S6B). These results demonstrat-
ed that ceritinib is a P-gp substrate.3.5. P-gp Inhibitors Resensitized Cells to Ceritinib, Crizotinib, or Docetaxel
To overcome ceritinib resistance caused by P-gp overexpression, we
treated each cell linewith ceritinib and the P-gp inhibitorMS209, verap-
amil, or the BCRP inhibitor fumitremorgin C (FTC). MS209 and verapa-
mil, but not FTC, sensitized patient-derived JFCR013-2 cells as well as
P-gp overexpressing H3122 clone to ceritinib, crizotinib and docetaxel
(Figs. 7A, S7A and S7B). Consistently, ceritinib withMS209 or verapamil
effectively suppressed ALK phosphorylation (Fig. 7B) and inhibited
phospho-ALK reactivation when the cells were treated with 1 μM of
ceritinib (Fig. 7C). In addition, MS209 treatment also re-sensitized the
Fig. 6.Ceritinib is a P-gp substrate and P-gp inhibition reduces drug export. (A) JFCR013-2 cells and shABCB1-(#86) induced JFCR013-2 cells incubatedwith 14C-labeled ceritinib (100 nM)
plus verapamil (10 μM) or MS209 (5 μM) at 37 °C. At the indicated time points, incorporated 14C-ceritinib was measured using a liquid scintillation counter. (B) K562 and P-gp-overex-
pressing K562/VCR cells incubated with 14C-labeled ceritinib (100 nM) plus verapamil (10 μM) or MS209 (5 μM) for 8 h at 37 °C. After washing the cells, incorporated 14C-ceritinib was
measured using a liquid scintillation counter.
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alectinib or PF-06463922 (Figs. S3 and S4).
Because MS209 was subjected to clinical evaluation in an advanced
breast cancer patient and found to be both safe and tolerable (Saeki
et al., 2007), we evaluated the efﬁcacy of ceritinib with MS209 in vivo.
JFCR013-2 cells were subcutaneously injected into mice, which were
subsequently treated with ceritinib plus MS209. The results showed
that the co-administration of ceritinib with MS209, but not ceritinib
monotherapy, inhibited tumor growth without affecting body weight
(Figs. 7D, E, S8A, and S8B). Ceritinib and MS209 in combination
inhibited phospho-ALK activation in the JFCR013-2 xenograft tumor
(Fig. S8C). In addition, alectinib and PF-06463922 more effectively
inhibited the growth of the JFCR013-2 xenograft tumor (Fig. S9).
3.6. P-gp Overexpression Mediated Drug Resistance in ALK-rearranged
NSCLC
To further examine the signiﬁcance of P-gp overexpression in
ceritinib and/or crizotinib resistance in ALK-rearranged NSCLC, we ex-
amined P-gp expression by IHC analysis in 30 treatment-naïve surgical
specimens of ALK-rearranged NSCLC but found no tumor overexpress-
ing P-gp (Fig. S10). Next, we examined P-gp expression in tumors of
progressed ALK-rearranged NSCLC treated with either of the ALK-TKIs
and found two cases of P-gp overexpression in ALK-rearranged NSCLC
(Fig. 8A). In one case, JFCR025 showed P-gp overexpression in both
pre-ALK-TKI-treated and post-ALK-TKI-treated tumors obtained from
an ALK-rearranged large cell neuroendocrine carcinoma patient
(LCNEC; Fig. 8B and Supplementary Fig. S11). From the ceritinib-
treated resistant tumor biopsy, we established the cell line JFCR025
and found that JFCR025 cells harbor the L1196M gatekeeper mutation
with P-gp overexpression (Figs. 8A, C, and Supplementary Fig. S12A).
The JFCR025 cells showed ceritinib resistance but were sensitive to
ceritinib+MS209 (Fig. 8D and Supplementary Fig. S12B). In the second
case, we identiﬁed P-gp overexpression in a metastatic ALK-rearranged
lung adenocarcinoma patient who received crizotinib following
ceritinib (MGH015). P-gp overexpression was observed in the solid
components of the crizotinib-resistant tumor but not in the bronchiolo-
alveolar carcinoma (BAC) component of crizotinib-resistant tumor.
P-gp overexpression was also observed in bone-metastatic regions
relapsing after 8months of ceritinib treatment (Figs. 8E and S13). As de-
scribed in our previous report (Katayama et al., 2012), crizotinib-
resistant tumors in the solid component, but not in the BAC component,showed high Ki67 levels, cKIT gene ampliﬁcation, and overexpression
of its ligand, SCF. These results suggest that P-gp overexpression
decreased cellular crizotinib or ceritinib levels and contributed to the
resistance.
4. Discussion
We identiﬁed an acquired ceritinib-resistancemechanism caused by
P-gp overexpression in an ALK-rearranged NSCLC patient who was re-
ceiving ceritinib therapy. We also demonstrated that ceritinib is a P-gp
substrate and that P-gp inhibition reversed ceritinib and crizotinib
resistance. While our manuscript was under review, it was reported
that brain accumulation of ceritinib is restricted by P-gp and BCRP
(Kort et al., 2015). For ALK-rearranged NSCLC patients, treatment with
ALK-TKIs, such as crizotinib, ceritinib, or alectinib often leads to conspic-
uous tumor shrinkage; however, tumors inevitably relapse because of
acquired resistance approximately within 1–2 years of treatment, simi-
lar to what is known for imatinib-treated CMLwith BCR-ABL- (Branford
et al., 2002) or EGFR-TKI-treated EGFR-mutated NSCLC (Engelman and
Janne, 2008; Kobayashi et al., 2005). Unlike lung cancers with EGFRmu-
tations, various crizotinib resistance mutations have been identiﬁed in
crizotinib-treated ALK-rearranged NSCLC. In addition, ALK fusion gene
ampliﬁcation has also been identiﬁed as a crizotinib resistance mecha-
nism. Ceritinib is a potent oral ALK inhibitor, which has been shown to
be effective for the treatment of naïve and crizotinib-treated ALK-
rearranged NSCLC patients (Shaw et al., 2014). However, acquired
ceritinib resistance also occurs, such as G1202R or F1174C/V mutations
in the ALK kinase domain (Friboulet et al., 2014). Similarly, G1202R or
I1171T/N/S mutations in ALK have been identiﬁed as an alectinib resis-
tancemutation. In addition,MET gene ampliﬁcation has also been iden-
tiﬁed in an alectinib-resistant patient in whom the tumor responded to
crizotinib, which is a potentMET inhibitor. Apart from alterations in the
ALK gene, bypass pathway activation mediated crizotinib resistance,
such as EGFR activation, KIT ampliﬁcation with SCF upregulation, or
IGF1R activation has been identiﬁed. However, themechanismunderly-
ing crizotinib, ceritinib and alectinib resistance remains largely un-
known in many cases (Katayama et al., 2012; Shaw and Engelman,
2013; Gainor et al., 2013; Lovly et al., 2014). Recently, crizotinib was
shown to be exported by P-gp, resulting in decreased penetration of
the blood–brain barrier by P-gp (Chuan Tang et al., 2014). Because
the use of crizotinib following ceritinib treatment showed minimal
effect in our patient (JFCR013), we suspected P-gp upregulation as a
Fig. 7.P-gp inhibitor treatment sensitized the cells to ceritinib invitro and in vivo. (A) JFCR-013-2 cells treatedwith the indicated concentrations of ceritinibplus verapamil (10 μM),MS209
(5 μM), or FTC (5 μM) for 72h. After incubation, cell viabilitywasmeasuredusing theCellTiter-Glo assay. Calculated IC50values are shown in the lower table. (B, C) JFCR-013-2 cells treated
with the indicated concentrations of ceritinibwith orwithout P-gp inhibitor MS209 (5 μM) or verapamil (10 μM) for 3 h (B) or for 1–48 h (C). Cell lysates were analyzed by immunoblot-
ting with the indicated antibodies. (D, E) JFCR013-2 cells were subcutaneously injected into nude mice. After the tumor achieved a size of approximately 100 mm3, the mice were
randomized by tumor size and daily treatment with 50 mg/kg of ceritinib with or without 200 mg/kg of MS209 was started. Tumor volumes were measured as follows: 0.5 ×
length × width × width. Tumor sizes relative to day 0 are shown in (D), and changes in body weight are shown in (E).
63R. Katayama et al. / EBioMedicine 3 (2016) 54–66mechanism of crizotinib resistance. Among the family of ATP-binding
cassette proteins, P-gp is most extensively characterized. Its overex-
pression is shown to be sufﬁcient to confer chemotherapeutic drug re-
sistance to both cell cultures and animal models of human cancers. To
date, attempts to improve anticancer therapy by the co-administration
of various P-gp inhibitors, including MS209, with chemotherapeutic
agents have been disappointing. In addition, the limited success of a
combination therapy of a P-gp inhibitor with a chemotherapeutic
agent was mainly because of undesirable toxicities. Although we did
not observe any severe adverse effects in our mouse experiments, wemust carefully consider the beneﬁts and undesirable toxicities of
molecular-targeted drugs in combination with the use of a P-gp inhibi-
tor.Many studies have investigated P-gp-associated drug resistance, but
very fewhave described clinical cases of P-gp-mediated drug resistance;
in particular, molecular-targeted agent resistance in NSCLC. In the
JFCR013 cells, P-gp overexpression was not caused by ABCB1 gene am-
pliﬁcation. mRNA expression in JFCR013 cell lines was substantially
higher than that in H3122 or ALK-TKI-naïve patient-derived JFCR018-
1 cells, in which P-gp expression was barely detectable. When we
continuously treated the H3122 tumor-bearing mice with ceritinib
Fig. 8. P-gp overexpression in ALK-rearrangedNSCLC clinical specimens. (A) ALKmutation status and P-gp expression status in an ALK-TKI-resistant tumor before and after ALK-TKI treat-
ment. (B, E) IHC analysis of P-gp protein expression inpre-alectinib- andpost-ceritinib-treated JFCR025 specimens (B) andpre-crizotinib-, post-crizotinib-/pre-ceritinib-, or post-ceritinib-
treatedMGH015 specimens (E). (C) H3122 and ceritinib-resistant patient-derived JFCR025 cells were analyzed by immunoblotting with the indicated antibodies. (D) JFCR025 cells were
treated with the indicated concentrations of ceritinib, crizotinib, alectinib or PF-06463922 with or without MS209 (5 μM) for 72 h. After incubation, cell viability was measured using the
CellTiter-Glo assay.
64 R. Katayama et al. / EBioMedicine 3 (2016) 54–66more than 2 months, we found that one tumor overexpressed ABCB1
mRNA (230 fold higher than the untreated H3122 xenograft tumor)
without ABCB1 gene ampliﬁcation (data not shown). Thus, ABCB1overexpression may be epigenetically regulated. Hence, further studies
are needed to clarify themechanism of ABCB1 upregulation in ceritinib-
resistant cell lines.
65R. Katayama et al. / EBioMedicine 3 (2016) 54–66In addition, a single case of LCNEC harboring an EML4-ALK rear-
rangement that confers crizotinib resistance was recently reported
(Omachi et al., 2014). However, in that study, the investigators did not
explore the potential mechanisms of resistance. In the present study,
we experienced a case of LCNEC overexpressing P-gp in both pre- and
post-ALK-TKI-treated specimens, for which the tumor responded to
alectinib. Indeed, we found that less than 1% of treatment-naïve lung
cancers overexpressed P-gp by tissue microarray examination of 1477
lung cancer surgical specimens. Becausewe only detected fewP-gp pos-
itive cases, we do not know whether P-gp expression links with cancer
phenotypes. In the alectinib-, crizotinib-, and ceritinib-resistant tumor
cells (JFCR-025), the L1196M gatekeeper mutation with P-gp overex-
pression was identiﬁed. In addition to our data in this study, alectinib
and PF-06463922 were found not to be a P-gp substrate in a former
study (Kodama et al., 2014; Johnson et al., 2014). In another case
(MGH015) with P-gp overexpression, we previously identiﬁed KIT am-
pliﬁcation with upregulation of the KIT ligand SCF in the solid compo-
nent of a crizotinib-resistant tumor. In our previous study, we showed
that SCF treatment conferred moderate crizotinib resistance in H3122
cells overexpressing KIT. However, in this study, we found that P-gp
was also overexpressed in the solid part of the tumor. Furthermore,
P-gp overexpression was observed in a ceritinib-resistant tumor me-
tastasized to the bone. Because P-gp contributes to the pump-out of
the ALK inhibitors crizotinib and ceritinib, resulting in decreased
sensitivity to crizotinib or ceritinib, activation of the bypass pathway
(e.g., KIT) with P-gp overexpression may confer complete ALK-TKI
resistance. Therefore, further studies on the frequency andmechanisms
of P-gp overexpression in resistant tumors are needed to determine
therapeutic strategies to prevent or overcome drug resistance in ALK-
positive NSCLC. In particular, we also found that the feedback activation
of EGFR and MET was also identiﬁed by the RTK-array when the
JFCR013-2 cells were completely inhibited ALK by ceritinib with
MS209 or alectinib treatment. However, RTKs re-activation did not
largely contribute to ALK-TKI resistance in JFCR013-2, because erlotinib
(EGFR inhibitor) and PHA665752 (MET inhibitor) slightly sensitized the
cells to ALK inhibition (alectinib or ceritinib plus P-gp inhibition). These
results suggest that P-gp overexpression is the main cause of ceritinib
resistance (and crizotinib) in JFCR013-2 cells. As described in the result
section, gene ampliﬁcation or mutation of EGFR, MET and KIT was not
identiﬁed in JFCR013-2 cells.
In addition, ABC-transporters are importantmarkers for the isolation
and analysis of stem cells and cancer propagating (stem) cells (Goodell
et al., 1996; Zhou et al., 2001; Chiba et al., 2006; Haraguchi et al., 2006;
Hirschmann-Jax et al., 2004; Kondo et al., 2004). We previously report-
ed that ABCG2 was highly expressed on the surface of cancer stem-like
side population (SP) cells from various cancer cell lines. Treatment with
MS209 (dofequidar), an inhibitor of both P-gp and ABCG2, effectively
sensitize the cancer stem-like SP cells to chemotherapeutic agent such
as mitoxantrone or CPT-11 (Katayama et al., 2009). In this study, we
showed that P-gp overexpression plays an important role in acquired
crizotinib and ceritinib resistance. In addition, our results imply that
the existence of ABC transporters-overexpressing cells as a minor pop-
ulation in the TKI treatment-naïve cancer may be a seed of resistant
tumor development, resulting in the prevention of complete cure of
cancer by TKIs, such as ceritinib or crizotinib. Further studies are needed
to clarify the importance of ABC transporters (P-gp) in acquired TKI
resistance and innate TKI resistance.
At this moment, multiple ALK-TKIs are used in the clinic and others
are under clinical evaluation. Each next-generation ALK-TKI has a
different sensitivity to crizotinib-resistant mutations. From this study,
we found that P-gp overexpression causes ceritinib and crizotinib
resistance in patients; crizotinib and ceritinib, but not alectinib and
PF-06463922, are substrates of P-gp. Thus, our results suggest that de-
termination of P-gp expression by IHC in addition to testing the genetic
alteration, and choosing ALK-TKIs based on the P-gp expression may be
very helpful to maximize ALK-TKIs therapy.Author Contributions
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